Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells

Leukemia

Volumn 25, Issue 6, 2011, Pages 985-994

  Allan, E K ^a,b   Holyoake, T L ^a   Craig, A R ^c   Jorgensen H G ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

^c ChemGenex Therapeutics Inc   (United States)

Author keywords

BcrAbl; CML; leukaemic stem cells; Mcl 1; omacetaxine

Indexed keywords

CD34 ANTIGEN; HOMOHARRINGTONINE; IMATINIB; PROTEIN MCL 1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CULTURE; CHRONIC MYELOID LEUKEMIA; COLONY FORMING CELL; DOWN REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STEM CELL;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; DOWN-REGULATION; HARRINGTONINES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 79958139921     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.55     Document Type: Article

References (28)

1. Kantarjian HM, Talpaz M, Santini V, Murgo A, Cheson B, O'Brien SM. Homoharringtonine: history, current research, and future direction. Cancer 2001; 92: 1591-1605.
2. de Lavallade H, Khorashad JS, Davis HP, Milojkovic D, Kaeda JS, Goldman JM et al. Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood 2007; 110: 2779-2780. (Pubitemid 47523217)
3. Quintas-Cardama A, Cortes J. Homoharringtonine for the treatment of chronic myelogenous leukemia. Expert Opin Pharmacother 2008; 9: 1029-1037. (Pubitemid 351593746)
4. Chen Y, Hu Y, Michaels S, Segal D, Brown D, Li S. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABLinduced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia 2009; 23: 1446-1454.
5. Quintas-Cardama A, Kantarjian H, Cortes J. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer 2009; 115: 5382-5393.
6. Powell RG, Weisleder D, Smith Jr. CR. Antitumor alkaloids for Cephalataxus harringtonia: structure and activity. J Pharm Sci 1972; 61: 1227-1230.
7. Gurel G, Blaha G, Moore PB, Steitz TA. U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome. J Mol Biol 2009; 389: 146-156.
8. Tang R, Faussat AM, Majdak P, Marzac C, Dubrulle S, Marjanovic Z et al. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther 2006; 5: 723-731.
9. Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005; 105: 3303-3311.
10. Akgul C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci 2009; 66: 1326-1336.
11. Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005; 105: 2093-2098. (Pubitemid 40731797)
12. Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y et al. A common signaling cascade may underlie 'addiction' to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 2006; 10: 425-435. (Pubitemid 44693471)
13. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532-4539. (Pubitemid 43801382)
14. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319-325.
15. Copland M, Pellicano F, Richmond L, Allan EK, Hamilton A, Lee FY et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2008; 111: 2843-2853.
16. Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007; 109: 4016-4019. (Pubitemid 46641755)
17. Konig H, Holyoake TL, Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 2008; 111: 2329-2338. (Pubitemid 351451441)
18. Kobayashi T, Ruan S, Clodi K, Kliche KO, Shiku H, Andreeff M et al. Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents. Oncogene 1998; 16: 1587-1591. (Pubitemid 28159906)
19. Legros L, Hayette S, Nicolini FE, Raynaud S, Chabane K, Magaud JP et al. BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge? Leukemia 2007; 21: 2204-2206. (Pubitemid 47423816)
20. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007; 109: 248-255. (Pubitemid 46106239)
21. Stone RM, Donohue KA, Stock W, Hars V, Linker CA, Shea T et al. A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol 2009; 63: 859-864.
22. Tipping AJ, Mahon FX, Zafirides G, Lagarde V, Goldman JM, Melo JV. Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia 2002; 16: 2349-2357. (Pubitemid 36054369)
23. Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 2006; 66: 10959-10966. (Pubitemid 44876995)
24. Tipping AJ, Deininger MW, Goldman JM, Melo JV. Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp Hematol 2003; 31: 1073-1080. (Pubitemid 37329751)
25. Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 2006; 103: 14907-14912. (Pubitemid 44527827)
26. Zhang B, Strauss AC, Chu S, Li M, Ho Y, Shiang KD et al. Targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 2010; 17: 427-442.
27. Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009; 119: 1109-1123.
28. Heaney NB, Pellicano F, Zhang B, Crawford L, Chu S, Kazmi SM et al. Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. Blood 2010; 115: 2241-2250.